Case Report

Management of Low-Grade Appendiceal Mucinous Neoplasm with Extensive Peritoneal Spread Diagnosed during Pregnancy: Two Case Reports and Literature Review

Ekaterina Baron, Vadim Gushchin, Mary Caitlin King, Andrei Nikiforchin, and Armando Sardi

Department of Surgical Oncology, The Institute for Cancer Care at Mercy, Mercy Medical Center, 227 St. Paul Place, 4th Floor Weinberg, Baltimore, Maryland 21202-2001, USA

Correspondence should be addressed to Armando Sardi; asardi@mdmercy.com

Received 29 June 2020; Revised 30 September 2020; Accepted 3 October 2020; Published 15 October 2020

Academic Editor: Ossama W. Tawfi

Copyright © 2020 Ekaterina Baron et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Clinical decisions in patients with peritoneal dissemination of low-grade appendiceal mucinous neoplasms (LAMN) diagnosed during pregnancy are challenging. However, their slow progression and favorable prognosis allow deferring definitive treatment until after spontaneous delivery, a reasonable period of breastfeeding, and fertility preservation. Case Presentation. Two pregnant patients were incidentally diagnosed with LAMN and extensive peritoneal spread at 20 weeks gestation and at cesarean section. Treatment with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in both cases was delayed until spontaneous delivery at term and breastfeeding in the first patient and breastfeeding and fertility preservation in the second patient. Both patients remain disease-free for over 5 years, and their children are healthy. The literature review highlights the challenges that physicians face in treating pregnant patients with stage IV appendiceal tumors. Conclusion. Pregnancy management decisions in patients with peritoneal spread from mucinous appendiceal tumor should be based on understanding the tumor biology and prognosis. Definitive treatment in pregnant patients with favorable tumors, such as LAMN, may be delayed until spontaneous delivery without compromising maternal survival.

1. Introduction

Treating neoplasms diagnosed during pregnancy entails weighing the risks and benefits for both mother and fetus. This requires considering multiple factors, such as tumor biology and prognosis, stage, gestational age at diagnosis, efficacy, toxicity, invasiveness of required treatment, and patient preferences. Particularly, the management of stage IV tumors with extensive dissemination during pregnancy poses additional challenges because it demands rapid and complex ethical decisions, which should be based on a deep understanding of tumor behavior and all available options.

Appendiceal mucinous neoplasms (AMN) are a rare group of malignancies with high heterogeneity of histopathologic subtypes and survival outcomes [1]. They range from low-grade neoplasms with favorable prognosis to high-grade tumors with significantly worse outcomes. At the same time, up to 20% of AMN present with peritoneal carcinomatosis (PC) [2], considered stage IV according to the American Joint Committee on Cancer (AJCC) 8th edition [3]. However, excellent long-term outcomes can be achieved in AMN with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) [4].

Diagnosis of PC during pregnancy is often considered to be a life-threatening condition where oncological concerns of the mother outweigh fetal risks. In the few published cases of PC from low-grade appendiceal tumors diagnosed during pregnancy, all managed with early labor induction, early cesarean section, or pregnancy termination in favor of faster definitive treatment [5–8]. However, the favorable prognosis and slow progression of LAMN, even with extensive PC, allows performing CRS/HIPEC after spontaneous delivery, which minimizes fetal risks without compromising maternal survival [9]. We present two unique cases of LAMN with PC...
diagnosed during pregnancy and managed with delayed CRS/HIPEC in the postpartum period accompanied by a literature review.

2. Case #1

A 31-year-old woman, gravida 2 para 1, with a history of asthma and anemia presented with a large intra-abdominal mass and ascites found incidentally on routine prenatal ultrasound (US) at 20 weeks gestation. Prior to that, the patient had an uneventful pregnancy and skipped US during the first trimester prenatal screening. An ovarian primary tumor was suspected and abdominopelvic magnetic resonance imaging (MRI) without contrast was performed within one week. MRI showed a disrupted appendiceal tip surrounded by soft tissues and fluid, as well as a substantial amount of abdominopelvic fluid with internal septations and debris, suggesting an appendiceal mucinous neoplasm with PC (Figures 1(a), 1(b), 2(a), 2(b)). Appendectomy, right salpingo-oophorectomy, omentectomy, and peritoneal biopsy were performed at 21 weeks gestation and pathology confirmed LAMN with cellular mucinous peritoneal implants (AJCC 8th stage IVA).

The patient was referred to a peritoneal surface malignancy center. Considering the favorable prognosis of LAMN even with extensive peritoneal spread, we assessed the risk of rapid tumor progression as low and recommended to defer definitive treatment until the postpartum period. A healthy 2,950 g (6.6 lbs.) male was born by uncomplicated spontaneous vaginal delivery at 38 weeks gestation. Staging with computed tomography (CT) of the chest, abdomen, and pelvis revealed multiple bilateral subdiaphragmatic, omental, mesenteric, and liver capsule mucinous implants and no extraperitoneal metastases. Tumor markers (CEA, CA 125, and CA 19-9) were normal.

After 4 months of breastfeeding, the patient underwent CRS/HIPEC with 40 mg mitomycin-C heated to 41-42°C for 90 minutes using the closed technique. The peritoneal cancer index (PCI) (range 0-39) [10] was 37. The surgery lasted 708 minutes with an estimated blood loss of 1,100 ml. Complete cytoreduction with residual small membranes on the small bowel (completeness of cytoreduction (CC) score 1) [4] was achieved. The postoperative period was complicated by anemia requiring red blood cell transfusion. The patient was discharged on postoperative day (POD) 9 with deep vein thrombosis (DVT) prophylaxis (40 mg of enoxaparin daily). However, she was readmitted twice: first with splenic and portal vein thrombosis (POD 15) and then with rectal bleeding (POD 30) after subsequent increase in anticoagulant dose. Regular follow-up included physical examinations; imaging of the chest, abdomen, and pelvis; and tumor markers every 6 months. At 63 months of follow-up, the patient remains disease-free and her child is healthy.

Figure 1: (a) Abdominal and pelvic MRI (sagittal plane) without IV contrast shows a gravid uterus and a substantial amount of T2 hyperintense fluid. (b) Abdominal and pelvic MRI (coronal plane) without IV contrast demonstrates an enlarged perforated appendix with extraluminal mucin (arrow) and T2 hyperintense fluid collection in the pelvis. B: bladder; C: cervix; F: fetus; IV: intravenous; MA: mucinous ascites; MRI: magnetic resonance imaging; U: uterus.

Figure 2: (a), (b) Abdominal and pelvic MRI without IV contrast ((a) coronal plane, (b) axial plane) shows a gravid uterus and significant amount of T2 hyperintense fluid, some of which is loculated with internal septations (arrows). B: bladder; F: fetus; IV: intravenous; MA: mucinous ascites; MRI: magnetic resonance imaging; P: placenta; U: uterus.
3. Case #2

A 31-year-old healthy woman, gravida 3 para 0, underwent cesarean section at 40 weeks gestation due to premature rupture of membranes and protracted labor and delivered a healthy 3,561 g (7.9 lbs.) male newborn. The patient had a history of lower back pain and mild anemia throughout the pregnancy and started experiencing diarrhea at 35 weeks. The full prenatal screening, including US in each trimester, revealed only an echogenic intracardiac focus of the fetus. Otherwise, the pregnancy was uneventful. During cesarean section, mucin originating from the appendix tip was found adherent to the uterus, right ovary, and fallopian tube. Appendectomy and peritoneal biopsy were performed, and pathology showed LAMN with PC (AJCC 8th stage IVA).

The chest, abdominal, and pelvic CT scan 3 weeks after delivery showed perihepatic and perisplenic capsular implants. Tumor marker assessment showed elevated CEA up to 8.8 ng/ml (N 0-5 ng/ml) and normal CA 125 and CA 19-9. Definitive treatment was delayed for breastfeeding and oocyte retrieval for cryopreservation of 4 embryos. Three months postdelivery, the patient underwent CRS/HIPEC with 90-minute perfusion of 40 mg mitomycin-C heated to 41-42°C. PCI was 27, and a complete cytoreduction was achieved (CC-score 0) after 487 minutes of surgery. The patient was discharged on POD 8 without major complications. She was readmitted several times over the last 5 years with small bowel obstructions that resolved nonoperatively.

Three years after CRS/HIPEC, the patient had a second child aged with delayed CRS/HIPEC, which, for patient #1, allowed spontaneous delivery of a healthy baby at 38 weeks with 4 months of breastfeeding and, for patient #2, 3 months of breastfeeding and cryopreservation of embryos that were eventually used successfully.

Diagnosis of PC at any stage of pregnancy is dramatic and associated with multiple challenges for both physician and patient. While there are numerous reports of appendiceal tumors diagnosed during pregnancy (Tables 1 and 2), we found only 6 with PC: 4 diagnosed during pregnancy and 2 of diagnosed during cesarean section. Of the four cases diagnosed during pregnancy, one was managed with preterm induction of labor at 35 weeks, two were managed with an early cesarean section at 30 and 33 weeks, and one was terminated at 18 weeks [5-8]. The time of definitive treatment in the two cases diagnosed at cesarean section is unknown as patients were referred to outside facilities [10, 11]. This may demonstrate that pregnancy termination or early labor induction with rushing CRS/HIPEC is a common strategy among peritoneal malignancy centers to treat patients with a peritoneal spread from AMN. In our center, we opted to delay CRS/HIPEC and allow the pregnancy to progress naturally.

The approach to delay definitive treatment in our cases was based on the well-known favorable prognosis of LAMN with extensive peritoneal spread treated with CRS/HIPEC. Two previously published cases of well-differentiated appendiceal adenocarcinoma with PC, which currently is considered to be the same grade (G1) and prognostic stage (IVA) as LAMN, managed their patients with early labor induction (35 weeks) and early cesarean section (33 weeks) followed by CRS/HIPEC in 2.5 weeks and 2 months, respectively [3, 5, 7]. Moreover, Haase et al. proposed managing peritoneal surface malignancies diagnosed during pregnancies with early induction and delaying treatment to 35 weeks if diagnosed in the 2nd trimester [5]. However, labor at 34-37 weeks of gestation refers to late preterm delivery and is associated with increased risk for numerous complications for the infant and should be avoided when possible [11]. We believe that the histopathology and disease pathogenesis must be considered carefully before inducing early delivery or termination. In case #1, the diagnosis was made in the 2nd trimester (20 weeks) during routine prenatal screening. Previous studies demonstrate an excellent prognosis of LAMN patients with 5-year overall survival up to 80-96% [9, 12]. This data suggests that the slow progression of LAMN allows for a natural progression of pregnancy and deferring CRS/HIPEC for a reasonable period. Therefore, we opted to postpone CRS/HIPEC for 8 months in case #1 until spontaneous at term delivery with subsequent breastfeeding and for 4 months in case #2 for breastfeeding and fertility preservation without compromising survival outcomes in either case as it is oncologically safe.

Diagnosing and staging AMN might be challenging during pregnancy due to the limited availability of safe diagnostic methods and nonspecific clinical presentation. Considering patient and fetus risks, only tests that may influence clinical management should be performed. Once peritoneal spread or local appendiceal tumor is suspected during prenatal pelvic US, additional imaging is required for staging and making decisions regarding diagnostic surgery. Abdominopelvic MRI without contrast is a safe and informative alternative to CT during pregnancy for clarifying the diagnosis of peritoneal lesions [13, 14]. The MRI in case #1 demonstrated a disrupted appendiceal tip and signs of mucin distributed throughout the abdomen and pelvis (Figures 1 and 2). These findings shifted our focus from initially suspected ovarian origin to appendiceal tumor and directed the diagnostic surgery.

Defining histopathologic subtype and stage is crucial for establishing treatment in patients with PC. We believe that diagnostic open or laparoscopic surgery for appendectomy, peritoneal biopsy, and thorough revision of the abdomen and pelvis is reasonable and should be performed in all patients with PC on imaging regardless of pregnancy stage. Laparoscopy has advantages in this case as it allows inspecting the majority of the abdominal cavity, including the upper abdomen. However, the use of laparoscopy in pregnant women is controversial. A meta-analysis of 11 retrospective...
| #  | Author (year)                | Age | Pathology                              | PC | Gestational age at dx | Clinical presentation | Treatment during pregnancy | Pregnancy outcome | Staging | Treatment postpregnancy | Time from pregnancy end to treatment | Complications                                                                 | Breastfeeding | Status | Child |
|----|-----------------------------|-----|----------------------------------------|----|-----------------------|-----------------------|--------------------------|---------------------|---------|------------------------|-------------------------------|-------------------------------------------------|----------------|--------|-------|
| 1  | Present case #1             | 31  | LAMN                                   | Yes| 2nd Tx (20 weeks)     | Routine prenatal screening | Appy, omentectomy, RSQ, peritoneal bx | Spontaneous vaginal delivery (38 weeks) | MR abdomen at 20 weeks; CT chest/abdominal after delivery | CRS/HIPEC (Mit-C) | 4 mos | POD 15: portal vein thrombosis; POD 30: rectal bleeding | 4 mos+12 mos milk donor | 5 yrs, NED | Healthy |
| 2  | Haase et al. (2010) [5]     | 30  | Well-differentiated mucinous adenocarcinoma | Yes| 2nd Tx (17 weeks)     | Routine prenatal screening | Appy, RSO, omental bx | Early induce vaginal delivery (35 weeks) | CT after delivery | CRS/HIPEC (Mit-C) + EPIC (5-FU) | 2.5 weeks | 28 | CC-1 | Neutropenia, prolonged ileus (NGT, TPN), DVT | -       | 5 yrs, NED | Healthy |
| 3  | Chiverto et al. (2012) [6]  | 36  | Infiltrating mucinous adenocarcinoma (T3N1M0) | Yes| 2nd Tx (18 weeks)     | Abdominal pain; 4 days | Dx lap, open appy | Terminated with misoprostol | Colonoscopy, CT chest/abdominal after termination | CRS/HIPEC (5-FU) + Oxaliplatin; adjuvant FOLFOX x8 cycles | - | 6 | Complete | - | NA | 10 yrs, NED, NA |
| 4  | Canuto et al. (2016) [7]    | 38  | Well-differentiated mucinous adenocarcinoma (pT4apN1) | Yes| 1st Tx                | Routine prenatal screening (R ovarian mass) | Laparoscopic R adnexectomy, peritoneal washings/36 weeks, 4 days | RDS prophylaxis; early C-section (33 weeks, 5 days) | - | CRS/HIPEC (Mit-C) + Cisplatin; adjuvant FOLFOX x6 mos | 2 mos | - | No residual tumor | - | - | 2 yrs, NED | Healthy |
| 5  | Sebire et al. (2008) [8]    | 29  | Moderately differentiated adenocarcinoma; liver metastasis | Yes| 3rd Tx (29 weeks)     | Abdominal pain, vomiting, UTI | None | C-section (30 weeks) | Abdom US (29 weeks); fine-needle liver bx | CRS adjuvant 5-FU/Epirubicin/carboplatin | 0 days (at C-section) | - | Residual tumor | - | - | 6 mos, AWD | Healthy |
| 6  | Donnemelid et al. (1986) [24] | 25  | Perforated invasive grade 1 mucinous adenocarcinoma | No| 1st Tx (31 weeks)     | Acute appendicitis with perforation | Urgent open appy, abscess drain | Induced vaginal delivery (33 weeks) | Chest X-ray, CT abd, colonoscopy 3 days after delivery | R hemicolecctomy | 9 days | NA | NA | None | - | 30 days | Healthy |
| 7  | Morgan et al. (2004) [25]   | 30  | Well-differentiated mucinous adenocarcinoma, negative peritoneal washings | No| 2nd Tx (26 weeks)     | Acute abdomen | Urgent open R hemicolecctomy | Spontaneous vaginal delivery (at term) | - | None | NA | NA | NA | None | - | 36 mos, NED | - |
| 8  | Zeteroğlu et al. (2003) [26] | 35  | Non-perforated appendiceal cystadenocarcinoma | No| 2nd Tx (21 weeks)     | Symptoms of acute appendicitis | Urgent appy | Terminated with misoprostol (21 weeks) | - | R hemicolecctomy, omentectomy | 3 days | NA | NA | None | NA | 1 yr, NED | NA |
| 9  | Casey et al. (2003) [27]    | 36  | Perforated appendiceal mucinous cystadenoma | No| 2nd Tx (21 weeks)     | Symptoms of acute appendicitis | Open appy | - | | | | | | | |
| 10 | Kahu and Croucher (2004) [28] | 42  | Mucous adenoma with mucocele | No| 1st Tx (5 weeks)      | US due to vaginal bleeding | None | Spontaneous miscarriage (anembryonic pregnancy) (7 weeks) | US at 5 weeks (adnexal mass); US in 3 Mos (enlarging ovarian mass) | Laparotomy/appy | 3 mos | NA | NA | NA | - | NA |
| 11 | Idris et al. (2015) [29]    | 35  | Mucocele                               | No| 2nd Tx (22 weeks)     | Symptoms of acute appendicitis | Open appy | Spontaneous vaginal delivery (at term) | - | None | NA | NA | NA | None | - | 1 yr, NED | - |
| #  | Author (year) | Age | Pathology | PC | Gestational age at dx | Clinical presentation | Treatment during pregnancy | Pregnancy outcome | Staging | Treatment postpregnancy | Time from pregnancy end to treatment | PCI | CC score | Complications | Breastfeeding | Status | Child |
|----|---------------|-----|-----------|----|----------------------|----------------------|--------------------------|----------------------|---------|------------------------|--------------------------------------|-----|----------|-----------------|---------------|--------|-------|
| 12 | Gilboa et al. (2008) [30] | 31 | Carcinoid tumor | No | 1st Tx (9 weeks) | Symptoms of acute appendicitis | Appy | Spontaneous miscarriage (5 days post-op) | - | - | - | NA NA | - | - | NA |
| 13 | Louzi et al. § (2006) [31] | 36 | Well-differentiated carcinoid tumor | No | 3rd Tx (34 weeks) | Symptoms of acute appendicitis | Urgent appy | Vaginal delivery (35 weeks) | - | R hemicolectomy | 2 weeks | NA NA | - | - | 23 mos, NED | Healthy |
| 14 | Piatek et al. (2016) [32] | 28 | Well-differentiated carcinoid with gangrenous appendicitis (KI-67: <1%) | No | 2nd Tx (25 weeks) | Symptoms of acute appendicitis | Appy | Spontaneous vaginal delivery (38 weeks) | MRI abd at 29 weeks, normal 24-hour urine 5-HIAA; whole body SPECT 3 Mos after delivery | None | NA NA NA NA | None | - | 1 yr, NED | Healthy |
| 15 | Berrios (1965) [33] | 23 | Carcinoid tumor | No | 1st Tx (2 months) | Symptoms of acute appendicitis | Appy | Spontaneous vaginal delivery (at term) | Negative liver scan during pregnancy | None | NA NA NA NA | - | - | 23 mos, NED | Healthy |
| 16 | Berrios (1965) [33] | 26 | Carcinoid tumor | No | 1st Tx (10 weeks) | Symptoms of ruptured ectopic pregnancy | Bleeding luteum cyst, incidental appy | - | - | None | NA NA NA NA | - | No FU | - |
| 17 | Pitiakoudis et al. (2008) [34] | 24 | Carcinoid tumor (0.5 cm) | No | 3rd Tx (32 weeks) | Symptoms of acute appendicitis | Appy | Spontaneous vaginal delivery (39 weeks) | - | - | - | NA NA | None | - | Healthy |
| 18 | Korkontzelos (2009) [35] | 23 | Carcinoid tumor (2.2 cm) | No | 2nd Tx (16 weeks) | Symptoms of acute appendicitis | Urgent appy | C-section (36 weeks) | R hemicolectomy | 0 days (at C-section) | NA NA | - | - | Healthy |

§Article in French. The cases reporting peritoneal spread at presentation are in italics. 5-FU: 5-fluorouracil; 5-HIAA: 5-hydroxyindoleacetic acid; Abd: abdomen; Appy: appendectomy; AWD: alive with disease; Bx: biopsy; CC: completeness of cytoreduction; CRS/HIPEC: cytoreductive surgery with hyperthermic intraperitoneal chemotherapy; C-section: cesarean section; CT: computed tomography; DVT: deep vein thrombosis; Dx: diagnosis/diagnostic; FOLFOX: folinic acid+5-fluorouracil+oxaliplatin; IVF: in vitro fertilization; LAMN: low-grade appendiceal mucinous neoplasm; Lap: laparoscopy; Mit-C: mitomycin C; mos: months; NA: not applicable; NED: no evidence of disease; NGT: nasogastric tube; PC: peritoneal carcinomatosis; PCE: peritoneal cancer index; Pelv: pelvis; R: right; RDS: respiratory distress syndrome; SPECT: single-photon emission computed tomography; TPN: total parenteral nutrition; Tx: trimester; US: ultrasound; UTI: urinary tract infection; XELOX: capecitabine+oxaliplatin; Yr (s): year (s).
| #  | Author (year) | Age | Pathology | PC | Gestational age at dx | Clinical findings during pregnancy | HIPEC referral | C-section surgery | C-section indication | Staging | Postpartum treatment | PCI | CC score | Complications | Breast-feeding | Status | Child |
|----|--------------|-----|-----------|----|----------------------|----------------------------------|----------------|------------------|--------------------|---------|-------------------|-----|----------|----------------|----------------|--------|-------|
| 1  | Present case #2 | 31  | LAMN      | Yes| 40 weeks             | Uneventful                       | Yes             | Appy             | Premature rupture of membranes Large size of previous babies with complicated delivery | CT chest/abd/pelv 3 weeks after C-section Postpartum tumor markers | Unknown (referred to outside facility for CRS/HIPEC) | -     | 27       | CC-0          | None             | 3 mos  | 6 yrs   | NED Healthy |
| 2  | Manan et al. (2010)[36] | 41  | Well-differentiated mucinous cystadenocarcinoma | Yes| At term              | Uneventful                       | Yes             | Appy, removal of all gelatinous material | Failure of cervical dilation | -       | -                 | -   | -        | None            | -               | None   | Healthy |
| 3  | Abdu et al. (2009) [37] | 36  | Well-differentiated mucinous adenocarcinoma | Yes| 40 weeks             | Lower abdominal pain at 37 weeks | Yes             | R hemoilectomy | -                 | -       | Unknown (referred to outside facility for CRS/HIPEC) | -   | -        | None            | -               | None   | Healthy |
| 4  | Inubashiri et al. (2019) [38] | 24  | LAMN      | No  | 38 weeks             | Uneventful                       | NA              | Appy             | Cephalopelvic disproportion | CT scan 1 month after C-section | None | NA      | NA            | None             | 6 days  | Healthy |
| 5  | Yohannes et al. (2019) [39] | 31  | LAMN      | No  | 38 weeks             | Uneventful                       | NA              | Appy             | Fetal hyposia, dysfunctional 2nd stage of labor | CT abd/pelv after C-section | None | NA      | NA            | -                | LTFU   | Healthy |
| 6  | Gallo et al. (2001) [40] | 29  | Well-differentiated mucinous cystadenocarcinoma | No | 38 weeks             | Uneventful                       | NA              | Appy             | Dysfunctional spontaneous delivery | Postpartum barium enema, abdominal scan, chest X-ray | R hemoilectomy | NA | -        | -             | 5 yrs, NED       | Healthy |
| 7  | Berrios (1965) [33] | 21  | Carcinoid tumor | No | At term              | Uneventful                       | NA              | Appy             | Cephalopelvic disproportion | -       | NA      | NA            | -                | -       | -       | Healthy |
| 8  | Berrios et al. (1965) [33] | 30  | Carcinoid tumor | No | 38 weeks             | -                              | NA              | Appy             | -                 | -       | NA      | NA            | -                | No FU   | -       | -          |
| 9  | Gökaslan et al. (2001) [41] | 30  | Carcinoid tumor | No | -                    | -                              | NA              | Appy             | -                 | None | NA      | NA            | -                | 5 mos, NED | Healthy |

The cases reporting peritoneal spread at presentation are in italics. Abd: abdomen; Appy: appendectomy; CC: completeness of cytoreduction; CRS/HIPEC: cytoreductive surgery with hyperthermic intraperitoneal chemotherapy; C-section: cesarean section; CT: computed tomography; Dx: diagnosis; FU: follow-up; LAMN: low-grade appendiceal mucinous neoplasm; LTFU: lost to follow-up; Mit-C: mitomycin C; mos: months; NA: not applicable; NED: no evidence of disease; PC: peritoneal carcinomatosis; PCI: peritoneal cancer index; Pelv: pelvis; Yrs: years.
studies showed that laparoscopic appendectomy is associated with higher fetal loss in pregnant women compared to open surgery [15]. At the same time, the largest study of almost 20,000 pregnant women reported a higher risk of adverse obstetrical events including miscarriages, preterm labor, and intrauterine death after open surgery [16]. In case #1, open appendectomy and peritoneal biopsy were performed, rather than full abdominal cavity exploration, for further histopathology assessment since PC had been already confirmed with MRI.

Regardless of the approach, surgical specimens obtained from the diagnostic surgery require meticulous pathologic assessment. Frozen sections should not be used to diagnose appendiceal tumors due to their complex pathology and low concordance between frozen sections and final pathology [17]. Fine needle biopsy of appendiceal neoplasm should also be avoided due to potential peritoneal spread and inadequate sampling [18]. Given the rarity and complexity of appendiceal neoplasm histopathology, we recommend the removal of the entire appendix and revision of slides at a specialized peritoneal surface malignancy center as soon as possible. This condition is uncommon in the absence of cirrhosis and other causes of portal hypertension and usually represents a hypercoagulative state [20]. Of 788 CRS/HIPEC procedures at our center, only 3 (0.4%) patients developed this complication. Generally, pregnancy and the postpartum period are associated with an increased risk of venous thrombosis compared to

| Scenario | Treatment Options | Amn Management | C-section | MRI | US | PC Diagnosis |
|----------|-------------------|---------------|-----------|-----|----|-------------|
| Positive resection margins | Discus with patient | Consider delivery at term | Referral to CRS/HIPEC center | | | |
| Negative resection margins | | | Surveillance | | | |
| Complete resection | | | Cesarectomy | | | |
| Partial resection | | | Right hemicolectomy | | | |

**Figure 3:** Algorithm of appendiceal mucinous neoplasm management diagnosed during pregnancy. The algorithm here is consistent with that for the first two scenarios except pregnancy management. AMN: mucinous appendiceal neoplasm; CRS/HIPEC: cytoreductive surgery with hyperthermic intraperitoneal chemotherapy; C-section: cesarean section; MRI: magnetic resonance imaging; PC: peritoneal carcinomatosis; US: ultrasound.
the general population with the highest risk in the postpartum period [21, 22]. Additionally, major surgeries and malignancies also exacerbate this risk [23]. Thus, postpartum women requiring CRS/HIPEC are extremely vulnerable to life-threatening thrombosis. Therefore, adequate antithrombotic prophylaxis is crucial and must be routinely performed during and after CRS/HIPEC in postpartum patients. Physicians should also be cognizant of the high risk for thrombosis in these patients.

5. Conclusion

The presented cases demonstrate that LAMN patients with peritoneal carcinomatosis diagnosed during pregnancy may defer definitive treatment of CRS/HIPEC until the postpartum period. Treatment delay allows for spontaneous delivery, breastfeeding, and fertility preservation without compromising the mother or newborn survival. We believe our clinical experience will help guide physicians in clinical decision-making in these challenging situations and reduce both patient and fetus risks.

Data Availability

The data used to support the findings of this study are restricted by the Mercy Medical Center IRB in order to protect patient privacy. Data is available upon request from the corresponding author for researchers who meet the criteria for access to confidential data.

Consent

Written informed consent was obtained from both patients before conducting the study. A copy of the consent is available for review by the Editor-in-Chief of this journal.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

References

[1] H. A. Choudry and R. K. Pai, "Management of mucinous appendiceal tumors," Annals of surgical oncology, vol. 25, no. 8, pp. 2135–2144, 2018.
[2] R. M. Smeenk, M. L. van Velthuysen, V. J. Verwaal, and F. A. Zoetmulder, "Appendiceal neoplasms and pseudomyxoma peritonei: a population based study," European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, vol. 34, no. 2, pp. 196–201, 2008.
[3] M. B. Amin and S. B. Edge, AJCC cancer staging manual, Springer, 2017.
[4] P. H. Sugarbaker, "New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?", The Lancet Oncology, vol. 7, no. 1, pp. 69–76, 2006.
[5] E. Haase, D. Yoo, and P. H. Sugarbaker, "Management of appendiceal pseudomyxoma peritonei diagnosed during pregnancy," World Journal of Surgical Oncology, vol. 7, no. 1, p. 48, 2009.
[6] Y. Chiverto, E. Cabezas, T. Pérez-Medina, and L. Sanfrutos-Llorente, "Infiltrating mucinous appendicular carcinoma during pregnancy. A case report and review of the literature," Journal of Obstetrics and Gynaecology, vol. 35, no. 8, pp. 856–858, 2015.
[7] E. M. Canuto, E. Picardo, D. Katsaros et al., "appendiceal pseudomyxoma peritonei in pregnancy: a case report," European journal of Obstetrics and Gynecology and Reproductive Biology, vol. 206, p. e141, 2016.
[8] N. J. Sebire, M. Osborn, A. Darzi, A. Farthing, and R. D. Goldin, "Appendiceal adenocarcinoma with ovarian metastases in the third trimester of pregnancy," Journal of the Royal Society of Medicine, vol. 93, no. 4, pp. 192-193, 2016.
[9] A. Nikiforchin, M. C. King, E. Baron et al., "Impact of mucin cellularity and distribution on survival in newly diagnosed patients with low-grade appendiceal mucinous neoplasm treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy," Annals of Surgical Oncology, 2020.
[10] P. Jacquet and P. H. Sugarbaker, "Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis," Cancer Treatment and Research, vol. 82, pp. 359–374, 1996.
[11] J. E. Williams and Y. Pugh, "The late preterm: a population at risk," Critical care nursing clinics of North America, vol. 30, no. 4, pp. 431–443, 2018.
[12] T. C. Chua, B. J. Moran, P. H. Sugarbaker et al., "Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy," Journal of Clinical Oncology, vol. 30, no. 20, pp. 2449–2456, 2002.
[13] R. N. Low and R. M. Barone, "Imaging for peritoneal metastases," Surgical oncology clinics of North America, vol. 27, no. 3, pp. 425–442, 2018.
[14] J. G. Ray, M. J. Vermeulen, A. Bharatha, W. J. Montanera, and A. L. Park, "Association between MRI exposure during pregnancy and fetal and childhood outcomes," Jama, vol. 316, no. 9, pp. 952–961, 2016.
[15] C. Wilasrusmee, B. Sukrat, M. McEvoy, J. Attia, and A. Thakkinstian, "Systematic review and meta-analysis of safety of laparoscopic versus open appendicectomy for suspected appendicitis in pregnancy," The British journal of surgery, vol. 99, no. 11, pp. 1470–1478, 2012.
[16] A. Sachs, J. Guglielminotti, R. Miller, R. Landau, R. Smiley, and G. Li, "Risk factors and risk stratification for adverse obstetrical outcomes after appendectomy or cholecystectomy during pregnancy," JAMA surgery, vol. 152, no. 5, pp. 436–441, 2017.
[17] W. Zhang, C. Tan, M. Xu, and X. Wu, "Appendiceal mucinous neoplasm mimics ovarian tumors: challenges for preoperative and intraoperative diagnosis and clinical implication," European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, vol. 45, no. 11, pp. 2120–2125, 2019.
[18] J. C. Zuzarte, Y. C. Liu, and A. M. Cohen, "Fine needle aspiration cytology of appendiceal mucinous cystadenoma: a case report," Acta Cytologica, vol. 40, no. 2, pp. 327–330, 1996.
[19] J. Jedrziewicz, Y. Tateishi, R. Kirsch et al., "Impact of referral center pathology review on diagnosis and management of
